ARK Genomic Revolution ETF vs SOLAI Limited — how do they compare? ARK Genomic Revolution ETF trades at $44.45, while SOLAI Limited trades at $3.72 (market cap $16.69M). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals.
| ARKG | SLAI | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $44.55 | $26.74 |
52-Week Low | $24.02 | $2.74 |
Market Cap | — | $16.69M |
Enterprise Value | — | $16.33M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SLAI trades at $3.72 with no recent price movement. The company faces severe financial distress with negative gross profit margin of -44.87% and net income margin of -134.63% for 2025. Technical indicators show a bullish signal despite fundamental weakness. Recent developments include a 7:1 reverse stock split effective July 2026 and NYSE delisting proceedings initiated in July 2026 following multiple compliance notices.
Investment outlook remains highly speculative given the company's financial deterioration and exchange delisting risk. The acquisition of NEURALAND stake and Solode Neo product launch provide potential growth catalysts, but current negative profitability and cash flow challenges outweigh near-term opportunities. Analyst consensus shows 100% hold rating with no buy recommendations.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →